SynthesisHistopathology2022
Microsatellite instability in rectal cancer: what does it mean? A study of two randomized trials and a systematic review of the literature.
Synthesis in Histopathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer.International journal of clinical oncology · 2025Guideline
- Universal Tumor Screening in Colorectal Cancer: Role of MMR Immunohistochemistry for Lynch Syndrome and Early-Onset CRC.Cancers · 2026Article
- ASO Practice Guidelines Series: Resectable Colorectal Cancer.Annals of surgical oncology · 2026Review
- Site- and age-dependent associations between Fusobacterium nucleatum and colorectal cancer mortality.Cancer · 2026Article
- Primary Tumor-Associated Loss of the Y Chromosome and Clinical Outcome in Metastatic Colorectal Cancer.Genes, chromosomes & cancer · 2026Article
- Prognostic and Treatment-Associated Survival Effects of Microsatellite Instability Across Disease Stages in Colon Cancer: An NCDB Analysis.Journal of gastrointestinal cancer · 2026Article
- Lymph node morphology as an MRI biomarker for microsatellite instability in rectal cancer.Abdominal radiology (New York) · 2026Observational
- Study on predicting microsatellite instability in rectal cancer using TCancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Local Recurrence Rates in Locally Advanced Rectal Cancer Are Higher with KRAS Codon 13 Mutations.Journal of gastrointestinal cancer · 2025Article
- Article
- Applying next-generation sequencing to detect microsatellite instability in pan-cancer patients: a retrospective study of 35,563 Chinese cases.NPJ precision oncology · 2025Article
- Prognosis and influencing factors of patients with different lymph node statuses after pathological complete response to neoadjuvant chemoradiotherapy in rectal cancer.Oncology letters · 2025Article
- Multimodal Preoperative Management of Rectal Cancer: A Review of the Existing Guidelines.Medicina (Kaunas, Lithuania) · 2025Review
- Positive lateral lymph node turned negative after neoadjuvant therapy-surgery or observation?Techniques in coloproctology · 2025Review
- Rectal Cancer: Exploring Predictive Biomarkers Through Molecular Pathways Involved in Carcinogenesis.Biology · 2024Review
- IMMUNOREACT 9 metachronous rectal cancers have high HLA-ABC expression on healthy epithelium but a lower infiltration of CD3+ T cells than primary lesions.Scientific reports · 2024Article
- Review
- Treatment of Microsatellite-Unstable Rectal Cancer in Sporadic and Hereditary Settings.Clinics in colon and rectal surgery · 2024Review
- Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.Cancer treatment and research · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
aimCurrently, compelling evidence illustrates the significance of determining microsatellite instability (MSI) in colorectal cancer (CRC). The association of MSI with proximal CRC is well established, however, its implications in patients with rectal cancer remain undefined. We therefore aimed to determine the role of MSI with respect to incidence and outcome in patients with rectal cancer. METHODS AND
resultsFor this we examined patients from two prospective phase III trials: TME trial and PROCTOR-SCRIPT trial (n = 1250). In addition, we performed a literature review to evaluate the overall prevalence, the effect on survival and the response to neo-adjuvant treatment in patients with MSI rectal cancer compared with microsatellite stable (MSS) rectal cancer. Our TME and PROCTOR-SCRIPT cohort showed no differences in terms of overall survival (OS) (hazard ratio [HR] 1.00, 95% confidence interval [CI] 0.69-1.47) and disease-free survival (DFS) (HR 1.00, 95% CI 0.68-1.45) in patients with MSI compared to MSS rectal cancer. The total number of MSI cases in all included studies (including our own) was 1220 (out of 16,526 rectal cancer patients), with an overall prevalence of 6.7% (standard error 1.19%). Both for OS as for DFS there was no impact of MSI status on prognosis (HR 1.00, 95% CI 0.77-1.29 and HR 0.86, 95% CI 0.60-1.22, respectively). The risk ratio (RR) for downstaging and pathological complete response showed also no impact of MSI status (RR 1.15, 95% CI 0.86-1.55 and RR 0.81, 95% CI 0.54-1.22, respectively).
conclusionRectal cancer patients with MSI form a distinct and rare subcategory, however, there is no prognostic effect of MSI in rectal cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.